| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| J M Brotchi. The neural mechanisms underlying levodopa-induced dyskinesia in Parkinson's disease. Annals of neurology. vol 47. issue 4 Suppl 1. 2000-04-21. PMID:10762137. |
treatment-related dyskinesias are the major limitation of dopamine replacement therapies such as levodopa in parkinson's disease (pd). |
2000-04-21 |
2023-08-12 |
Not clear |
| D J Brooks, P Piccini, N Turjanski, M Samue. Neuroimaging of dyskinesia. Annals of neurology. vol 47. issue 4 Suppl 1. 2000-04-21. PMID:10762143. |
dyskinesias are observed in the majority of parkinson's disease (pd) patients who have been chronically exposed to levodopa, and these may result from supersensitivity of postsynaptic striatal dopamine d1 and d2 receptors following loss of nigral dopaminergic projections. |
2000-04-21 |
2023-08-12 |
Not clear |
| C W Olanow, J A Obes. Preventing levodopa-induced dyskinesias. Annals of neurology. vol 47. issue 4 Suppl 1. 2000-04-21. PMID:10762145. |
current evidence indicates that dyskinesias develop in response to pulsatile stimulation of striatal dopamine receptors. |
2000-04-21 |
2023-08-12 |
Not clear |
| O Rasco. Medical treatment of levodopa-induced dyskinesias. Annals of neurology. vol 47. issue 4 Suppl 1. 2000-04-21. PMID:10762146. |
to prevent, at least partly, priming for dyskinesias can be attempted by delaying the need for levodopa, and/or reducing the cumulative dose of levodopa, using, for example, dopamine d2 agonists at the early stages of treatment. |
2000-04-21 |
2023-08-12 |
Not clear |
| O Rasco. Medical treatment of levodopa-induced dyskinesias. Annals of neurology. vol 47. issue 4 Suppl 1. 2000-04-21. PMID:10762146. |
to avoid the expression of dyskinesias in already primed patients, agents that act on either the dopamine or nondopaminergic receptors have been used. |
2000-04-21 |
2023-08-12 |
Not clear |
| T Boraud, E Bezard, J M Stutzmann, B Bioulac, C E Gros. Effects of riluzole on the electrophysiological activity of pallidal neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkey. Neuroscience letters. vol 281. issue 2-3. 2000-04-05. PMID:10704746. |
riluzole would represent an interesting alternative to dopamine therapy in parkinson's disease since it regularizes firing but does not cause dyskinesia. |
2000-04-05 |
2023-08-12 |
monkey |
| C M Queiroz, R Frussa-Filh. Effects of buspirone on an animal model of tardive dyskinesia. Progress in neuro-psychopharmacology & biological psychiatry. vol 23. issue 8. 2000-01-28. PMID:10631766. |
because it was also verified that chronic buspirone treatment was able to increase apomorphine-induced yawning behavior, the possibility is raised that buspirone attenuates reserpine-induced orofacial dyskinesia through the development of dopamine autoreceptor supersensitivity. |
2000-01-28 |
2023-08-12 |
rat |
| S Shiozaki, S Ichikawa, J Nakamura, S Kitamura, K Yamada, Y Kuwan. Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP. Psychopharmacology. vol 147. issue 1. 2000-01-24. PMID:10591873. |
current treatment of parkinson's disease (pd) is based on dopamine replacement therapy, but this leads to long term complications, including dyskinesia. |
2000-01-24 |
2023-08-12 |
Not clear |
| L Peacock, G Jensen, K Nicholson, J Gerlac. Extrapyramidal side effects during chronic combined dopamine D1 and D2 antagonist treatment in Cebus apella monkeys. European archives of psychiatry and clinical neuroscience. vol 249. issue 5. 1999-12-30. PMID:10591986. |
previous studies in non-human primates have shown that tolerance to dystonia occurs during chronic dopamine d1 (d1) but not d2 antagonism and induction/aggravation of oral dyskinesia (td) during d2 but not d1 antagonism. |
1999-12-30 |
2023-08-12 |
monkey |
| G Andringa, J C Stoof, A R Cool. Sub-chronic administration of the dopamine D(1) antagonist SKF 83959 in bilaterally MPTP-treated rhesus monkeys: stable therapeutic effects and wearing-off dyskinesia. Psychopharmacology. vol 146. issue 3. 1999-12-15. PMID:10541734. |
sub-chronic administration of the dopamine d(1) antagonist skf 83959 in bilaterally mptp-treated rhesus monkeys: stable therapeutic effects and wearing-off dyskinesia. |
1999-12-15 |
2023-08-12 |
monkey |
| B Henry, S H Fox, D Peggs, A R Crossman, J M Brotchi. The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society. vol 14. issue 5. 1999-11-10. PMID:10495035. |
dopamine replacement therapy in patients with parkinson's disease is plagued by the emergence of abnormal involuntary movements known as l-dopa-induced dyskinesias. |
1999-11-10 |
2023-08-12 |
marmoset |
| R Grondin, M Goulet, M Morissette, P J Bédard, T Di Paol. Dopamine D1 receptor mRNA and receptor levels in the striatum of MPTP monkeys chronically treated with SKF-82958. European journal of pharmacology. vol 378. issue 3. 1999-11-08. PMID:10493101. |
thus, neither dyskinesias nor tolerance can be exclusively related to an increase or decrease in striatal dopamine d1 receptors, respectively. |
1999-11-08 |
2023-08-12 |
monkey |
| R L Oliveri, G Annesi, M Zappia, D Civitelli, R Montesanti, D Branca, G Nicoletti, P Spadafora, A A Pasqua, R Cittadella, V Andreoli, A Gambardella, U Aguglia, A Quattron. Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD. Neurology. vol 53. issue 7. 1999-11-03. PMID:10534246. |
dopamine d2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in pd. |
1999-11-03 |
2023-08-12 |
Not clear |
| R L Oliveri, G Annesi, M Zappia, D Civitelli, R Montesanti, D Branca, G Nicoletti, P Spadafora, A A Pasqua, R Cittadella, V Andreoli, A Gambardella, U Aguglia, A Quattron. Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD. Neurology. vol 53. issue 7. 1999-11-03. PMID:10534246. |
to investigate whether polymorphisms in the genes for dopamine receptors d1 and d2 are associated with the risk of developing peak-dose dyskinesias in pd. |
1999-11-03 |
2023-08-12 |
Not clear |
| F Duri. Treating and preventing levodopa-induced dyskinesias: current and future strategies. Drugs & aging. vol 14. issue 5. 1999-10-15. PMID:10408734. |
the general approach to the treatment of peak dose dyskinesias is to maintain dopamine brain stimulation at as stable a level as possible by keeping plasma and brain levodopa concentrations in the therapeutic range (above the therapeutic threshold but below the dyskinesia threshold). |
1999-10-15 |
2023-08-12 |
Not clear |
| F Duri. Treating and preventing levodopa-induced dyskinesias: current and future strategies. Drugs & aging. vol 14. issue 5. 1999-10-15. PMID:10408734. |
stopping selegiline (deprenyl) therapy may reduce dyskinesias; reducing the dose of, or stopping treatment with, a dopamine agonist may also be beneficial. |
1999-10-15 |
2023-08-12 |
Not clear |
| M P Muriel, V Bernard, A I Levey, O Laribi, D N Abrous, Y Agid, B Bloch, E C Hirsc. Levodopa induces a cytoplasmic localization of D1 dopamine receptors in striatal neurons in Parkinson's disease. Annals of neurology. vol 46. issue 1. 1999-08-02. PMID:10401786. |
altered localization of d1 dopamine receptors may participate in the occurrence of side effects of levodopa therapy such as dyskinesia and fluctuations in motor performances. |
1999-08-02 |
2023-08-12 |
human |
| O Rascol, O Blin, C Thalamas, S Descombes, C Soubrouillard, P Azulay, N Fabre, F Viallet, K Lafnitzegger, S Wright, J H Carter, J G Nut. ABT-431, a D1 receptor agonist prodrug, has efficacy in Parkinson's disease. Annals of neurology. vol 45. issue 6. 1999-06-24. PMID:10360765. |
studies in animal models show a selective d1 receptor agonist with full functional efficacy compared with dopamine to have antiparkinsonian efficacy of similar magnitude to levodopa, without the same propensity for inducing dyskinesia. |
1999-06-24 |
2023-08-12 |
human |
| M Tariq, H A Khan, K A Moutaery, S A Dee. Tolerance to beta,beta'-iminodipropionitrile (IDPN)-induced neurobehavioural and vestibular toxicity in diabetic rats. Journal of applied toxicology : JAT. vol 19. issue 2. 1999-06-07. PMID:10215181. |
the treatment of diabetic rats with insulin normalized striatal dopamine (da) turnover but partially reversed diabetes-induced protection against idpn dyskinesia. |
1999-06-07 |
2023-08-12 |
rat |
| R A Hauser, T A Zesiewic. Management of early Parkinson's disease. The Medical clinics of North America. vol 83. issue 2. 1999-04-13. PMID:10093585. |
and (2) should dopamine agonists be used as initial symptomatic therapy in early disease rather than levodopa/pdi to reduce long-term disability and delay the onset of motor fluctuations and dyskinesia? |
1999-04-13 |
2023-08-12 |
Not clear |